News

US Treasury Secretary Scott Besant stated at the New York Economic Club that a strong US dollar does not refer to the Bloomberg Dollar Index, but rather to a foundation built through tax policy, regulation, and energy certainty. Scott Besant believes that a strong dollar is not at odds with robust manufacturing, and noted that fluctuations in the dollar exchange rate are merely price movements on a screen.

Glonghui, June 24｜Eli Lilly is accelerating the expansion of its global obesity treatment footprint. Patrik Jonsson, Executive Vice President of International Business at Eli Lilly, stated that after receiving regulatory approval in the US and UAE, Europe will be the next key market for the company’s product launches. Eli Lilly's oral weight loss drug is expected to be available in Europe as early as the second half of this year and at the latest by early 2027, and the company will replicate its US market strategy by promoting products via telemedicine platforms, e-commerce, and direct-to-consumer (DTC) channels. Unlike the US market, most obesity treatment costs in Europe are still primarily paid out-of-pocket by patients, with public healthcare systems offering relatively limited coverage for weight-loss drugs. Therefore, Eli Lilly plans to prioritize targeting the consumer market of those willing to pay out-of-pocket for weight-loss medication.

Lindsay Rosner, Head of Multi-Sector Investments for Asset and Wealth Management at Goldman Sachs, stated that the probability of a Federal Reserve rate hike in July is 50%. The Personal Consumption Expenditures report is a key factor, and the wealth effect from rising stock prices is a reason for the rate hike. Goldman Sachs has postponed its expected timeline for a rate cut to the end of 2027.